This HTML5 document contains 175 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33410172
rdf:type
wikibase:Item
schema:description
tieteellinen artikkeli wetenschappelijk artikel 2013年论文 บทความทางวิทยาศาสตร์ artigo científico (publicado na 2013) mokslinis straipsnis научна статия artykuł naukowy artikulong pang-agham 2013 nî lūn-bûn 2013年论文 مقالة علمية мақолаи илмӣ teaduslik artikkel naučni članak 2013年論文 2013年论文 article científic 2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված სამეცნიერო სტატია videnskabelig artikel (udgivet 2013) سائنسی مضمون 2013年论文 artículu científicu espublizáu en 2013 2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած wissenschaftlicher Artikel artigo científico 2013年論文 2013年论文 ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scienca artikolo επιστημονικό άρθρο научни чланак bilimsel makale artikull shkencor 2013年论文 2013年の論文 наукова стаття, опублікована у вересні 2013 мақолаи илмӣ article scientific artigo científico (publicado na 2013) vitskapeleg artikkel 2013年論文 научная статья articolo scientifico مقالهٔ علمی vědecký článek 2013年論文 artículo científico publicado en 2013 vedecký článok vitenskapelig artikkel articol științific 2013년 논문 tudományos cikk vetenskaplig artikel 2013年論文 מאמר מדעי bài báo khoa học научни чланак scientific article article scientifique (publié 2013)
p:P577
wds:Q33410172-47655546-79AD-4B7A-8B41-747A5EBCFDEF
wdt:P577
2013-09-03T00:00:00Z
p:P2860
wds:Q33410172-5E07D6D1-0AB8-41B9-854B-55C8B6C22E9F wds:Q33410172-48B814B5-ED4F-4EBB-90C1-957E1B9C95E7 wds:Q33410172-61DA8098-FEE0-47EE-AED9-5C24F56B1176 wds:Q33410172-6DF84B6E-54CA-4CEF-B1B3-9279FD1E5DFB wds:Q33410172-07D550BD-4EFD-4ADC-AF95-FDF8E1D08CAE wds:Q33410172-21D21CC8-CD81-4F8A-A535-0130C18EF0E7 wds:Q33410172-477884D8-697C-4B29-A193-E1F443E241B7 wds:Q33410172-F2027ABD-7DA6-4144-BC8E-084717F54F10 wds:Q33410172-EA333310-DDE9-40EA-B395-1482EADAAFB1 wds:Q33410172-EBCB8BC5-DCBE-4012-84E9-2CF85988AFDF wds:Q33410172-C1870AAB-FA86-4F66-8B92-FB58244A3C81 wds:Q33410172-D142C92F-1EF1-4991-A3BA-4AE7928A83B0 wds:Q33410172-BAAC44EE-258A-4D61-8E87-0C46DE2D9569 wds:Q33410172-BC8CEDE6-E64A-43E9-A8CA-59BA5B6D0B47
wdt:P2860
wd:Q34753416 wd:Q33377526 wd:Q33322921 wd:Q46549268 wd:Q34549410 wd:Q34008578 wd:Q81527272 wd:Q44975171 wd:Q24605861 wd:Q34585268 wd:Q39485433 wd:Q33402536 wd:Q33942495 wd:Q33348702
p:P2093
wds:Q33410172-1294F388-D729-467E-857D-BC78B366DA0D wds:Q33410172-2FB96125-B2C9-48C7-A396-22175970AD61 wds:Q33410172-52018F72-ED1E-4606-B031-5C96E8AB97BE wds:Q33410172-5F080F1F-75F1-4CA8-850A-C89068EF4F98 wds:Q33410172-78FF4D4C-7A2B-4BDC-BD33-FA0316C2D17A wds:Q33410172-704E58ED-AF86-4964-A4F4-6C82C1D1BF99 wds:Q33410172-877883A6-3BC3-4E38-9D59-BEC582580FC7
wdt:P2093
Xin Yu Christian Jacques Kevin Song Christine Chen Mohamed Zaki Valentina Ivanova Joaquin Martinez-Lopez
rdfs:label
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
skos:prefLabel
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
schema:name
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
p:P50
wds:Q33410172-C9A49A8E-0AAA-46D3-A641-07A1E316E1DD wds:Q33410172-D3B5E56A-5E5C-4B54-A696-F3ECEF6BEB34 wds:Q33410172-84681287-14C3-4495-8E35-4F41C8020190 wds:Q33410172-8CC81318-EF3C-4E71-969C-F9179FD0C7C0 wds:Q33410172-93FB7246-2D1C-41F3-8C6B-3FBAE65C6A0D wds:Q33410172-94D9EFF6-3082-49DE-84D3-CC93C37D27F4 wds:Q33410172-9DBDE231-BBD2-4DE8-9687-A24E002874BA wds:Q33410172-B0A2BA35-FB90-4223-B6F3-689D2A65B1FA wds:Q33410172-D905F02A-307D-46FF-9158-AD69E326F778 wds:Q33410172-311F311B-5294-4936-B79D-2C6EC4799AAC wds:Q33410172-447D993B-EA6A-4A0A-A412-FEE309732ECE wds:Q33410172-44C721F9-F176-4B10-ACF5-9413CCCC0A0B wds:Q33410172-681EAC11-37B1-4E01-A01F-939C37D4B2FD wds:Q33410172-70C764CB-7E6A-4AB5-90B5-DDC4A06A8263 wds:Q33410172-8137613B-54AF-4934-90F1-E7B444A3ABF6 wds:Q33410172-52F897D7-0248-4D6F-AB5B-473AD1F45621 wds:Q33410172-569F7275-702D-4981-A5B4-F645F56A26CC wds:Q33410172-56B0EBED-EFD3-4093-8302-285D2851298B
wdt:P50
wd:Q66419394 wd:Q26338766 wd:Q114429473 wd:Q87664147 wd:Q5930658 wd:Q96475433 wd:Q114442086 wd:Q114442085 wd:Q87013105 wd:Q47344831 wd:Q73546936 wd:Q57233657 wd:Q87734443 wd:Q89444137 wd:Q92116116 wd:Q100529915 wd:Q23061917 wd:Q89982374
p:P1476
wds:Q33410172-B9D6531C-3A2F-4E7B-BBBF-C6509C48E5C5
wdt:P1476
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
p:P304
wds:Q33410172-5DC5023F-CEB4-429B-976D-7B6FF0608BD0
wdt:P304
1055-1066
p:P31
wds:Q33410172-465E67E3-E07C-42A8-AF7C-76B4F8230EB4
wdt:P31
wd:Q13442814
p:P921
wds:Q33410172-3A5DBB21-3801-4D41-ACE6-3E731C800501 wds:Q33410172-ECE79354-F69F-4FCA-8D15-0367CFB464A3 wds:Q33410172-B17FD3B1-0222-41E9-B375-E11D350116C8
wdt:P921
wd:Q42824827 wd:Q467635 wd:Q422252
p:P698
wds:Q33410172-B55FAA8D-987B-4F11-9A5A-4CE961B8A5F0
wdtn:P698
n10:24007748
wdt:P698
24007748
p:P1433
wds:Q33410172-D503C52B-7003-423E-854A-648F36C25072
wdt:P1433
wd:Q13747613
p:P433
wds:Q33410172-07425CDC-734B-48D8-BB2C-E935B255C85F
p:P478
wds:Q33410172-6E229910-D0A2-417C-B723-D5977BCDC11D
wdt:P433
11
wdt:P478
14
p:P356
wds:Q33410172-1B67D4ED-2A76-4F7D-8634-CDF76AD98572
wdtn:P356
n11:S1470-2045(13)70380-2
wdt:P356
10.1016/S1470-2045(13)70380-2